Introduction

Hematopoietic stem cells (HSCs) mainly reside in the microenvironments in the bone marrow (BM), where they pass through multiple developmental steps to produce mature blood cells1,2. During hematopoietic stresses, such as injury, infection and niche disruption, HSCs become activated and participate in tissue generation, maintenance, and repair2,3. Under homeostatic conditions, HSCs preserve the potential for long-term self-renewal that retains stemness during division4 and the capacity for subsequent reconstitution5. However, under stress condition such as serial transplantation, HSCs can lose their capacity for self-renewal and reconstitution, a phenomenon referred to as stem cell exhaustion5. For the successful bone marrow transplantation, HSCs have to be engrafted into bone microenvironment and then be expanded. In other words, the key factors for reconstitution of HSC transplantation is the efficiency of HSC engraftment/homing and retention in the BM niche6. HSC homing and engraftment depend on the chemotactic axis7.

The Hippo pathway regulates the self-renewal and differentiation of stem and progenitor cells, and plays key roles in controlling organ size and regeneration8,9,10,11,12. Mammalian sterile-20 kinase 1 and 2 (Mst1/2), mammalian homologs of Hippo, are a core pair of serine-threonine kinase in the Hippo signaling pathway that regulate the cell cycle and apoptosis13,14,15,16. MST1/2 have also been implicated in hepatocellular sarcoma, intestinal adenocarcinoma, and lymphoma. Mst1/2 are expressed in most organs as well as the hematopoietic system17. Early studies identified an important role for MST1 and RAPL, an alternatively spliced form of RASSF5 (Ras association domain family member 5) that interacts with MST1, in lymphocyte trafficking and migration through integrin signaling18. Studies of Mst1-deficient mice have demonstrated that MST1 regulates the production of reactive oxygen species (ROS) through FOXO3A (forkhead box O3A), thereby preventing apoptosis of peripheral T cells14. In addition, it was recently shown that MST1/2 are capable of regulating NF-κB signaling in myeloid cells under conditions of infection19. MST1/2 also participate in the regulation of hematopoietic and endothelial progenitors in Xenopus20. These observations indicate that MST1/2 are important in hematopoietic cells; however, little is known about the roles of MST1/2 in HSC regulation.

In this study, we found that Mst1/2 control the production of mature hematopoietic cells. In addition, HSCs were functionally impaired in mice in which Mst1/2 were conditionally deleted, as evidenced by alterations in the steady-stated HSC population in BM and impaired function of Mst1/2-deficient HSCs under stress conditions. Mst1/2-deficient cells also showed a poor ability to engraft into BM compared with control cells. These data suggest that inefficient engraftment of Mst1/2-deficient BM cells in a transplantation setting is attributable to decreased homing ability. Collectively, our findings suggest that MST1 and MST2 regulate HSC function.

Material and Methods

Animal studies

Mst1Floxed/Floxed mice, kindly provided by Dr. T. Kinashi (Kansai Medical University), were interbred with conventional Mst2-knockout mice, after which Mst1fl/fl;Mst2-/-;Mx1-Cre mice were generated by crossing with a Mx1-Crestrain mouse21,22. For induction of Cre expression, Mst1fl/fl;Mst2-/-;Mx1-Cre mice were intraperitoneally (i.p.) injected with pIpC (polyinosinic–polycytidylic acid) every 2 days for 2 weeks23,24. For BM transplantation, lethally irradiated recipient mice were intravenously (i.v.) transplanted with competitor BM cells (0.5–2×106) from CD45.1 mice and test BM cells (0.5–2×106) from control or Mst1/2 double-knockout (DKO) mice. All mice were kept in a specific pathogen-free facility at Korea Advanced Institute of Science and Technology (KAIST). The Institutional Animal Care and Use Committee of KAIST approved all of the following research protocols (approval ID: KA2010–23), including the surgical procedures and animal care, and all methods were performed in accordance with the relevant guidelines and regulations.

Flow cytometric analysis

Flow cytometry was performed as described previously24. BM cells were collected from femurs and tibias by flushing with fluorescence-activated cell sorting (FACS) buffer, consisting of phosphate-buffered saline (PBS) containing 2% fetal bovine serum (FBS) and 0.1% sodium azide. Splenocytes were obtained by mincing spleens on a 40-μm cell strainer with FACS buffer. Peripheral blood cells were collected from the tail vein or heart. White blood cell preparations were obtained after lysing red blood cells with an ammonium-chloride-potassium (ACK) lysis buffer. White blood cells were detected with biotin-conjugated antibodies against CD4 (RM4–5), CD8a (53–6.7), GR1 (RB6–8C5), CD11b (3A33), B220 (RA3–6B2), Nk1.1 (PK136) and TER119; LSKs (LinSca1+cKit+ cells) were detected using Sca1-PE-Cy7 (D7) and cKit-APC (2B8) antibodies.

BrdU incorporation assay

Cells were obtained from mice 4 hours after injecting with BrdU (100 mg/kg, i.p.). Cells were then fixed, permeabilized and immunostained for cell surface markers (as detailed above) and BrdU using a BrdU FITC kit (BD Biosciences) as per the manufacturer’s instructions.

Short-term engraftment assay

Short-term engraftment assays were performed by transplanting 3 × 107 BM cells from Mst1/2-deficient or control (CD45.2+) mice into CD45.1+ mice. Three weeks after transplantation, donor cell chimerism was examined in BM, spleen, and thymus.

Homing assay

Homing assays were performed by transplanting carboxyfluorescein succinimidyl ester (CFSE)-labeled BM cells (4 × 106) from Mst1/2-deficient or control mice into lethally irradiated recipient mice. Sixteen hours after transplantation, CFSE+ cells were assessed in BM, spleen, and peripheral blood (PB).

Colony Formation Assays

For assessing hematopoietic progenitor cell activity, BM, spleen, and PB cells were counted and plated in methylcellulose medium (M3434, STEMCELL Technologies)24. The colony number is counted 7 days after plating.

Statistics

Sample sizes required for experiments were estimated based on preliminary results. No blinding or randomization was performed for any of the experiments. The statistical significance of differences between population means was assessed by two-tailed unpaired Student’s t-test, unless otherwise indicated. Statistically significant differences (*p ≤ 0.05, **p ≤ 0.01) for pairwise comparisons between the indicated data points are shown. Statistical comparisons between individual data points and groups were not performed. The Kaplan-Meier log-rank test was used to analyze mouse survival data.

Results

Effects of Mst1/2 conditional deletion on mature cell subsets under homeostatic conditions

To investigate the role of MST1 and MST2 in HSPCs, we crossed Mst1floxed/floxed;Mst2−/− mice with Mx1-Cre transgenic mice21,22 in which Cre recombinase is activated by administration of pIpC24. Consistent with previous studies on lymphopenia14, B cells were dramatically decreased in the BM, spleen and peripheral blood (PB) from Mst1floxed/floxed;Mst2−/−;Mx1-Cre mice (referred to as DKO; Fig. 1A). However, mild T cell lymphopenia was detected (data not shown). We also found that DKO mice showed erythropenia in the BM and myeloid expansion in BM, spleen, and PB (Fig. 1A).

Figure 1
figure 1

Pools of HSCs and progenitors are increased in Mst1/2-DKO mice. (A) The frequencies of B cells (B220) and myeloid cells (monocytes, Mac1+Gr1lo; neutrophils, Mac1+Gr1+) in the BM, spleen and PB, and erythroid cells (TER119) in the BM, from mice of the indicated Mst1/2 genotypes are shown. (B) The frequencies of LSK cells, HSCs and cycling HSCs were decreased in BM from Mst1/2-DKO mice. The frequencies of committed progenitors (LMPPs, CLPs, CMPs, GMPs and MEPs) were increased in BM from Mst1/2-DKO mice. (C) The total numbers of colonies produced in M3434 media from cells of mice of each genotype are indicated. Error bars indicate S.E.M. (*p ≤ 0.05, **p ≤ 0.01, n = 4).

The absolute numbers of LinSca1+cKit+ cells (LSKs), HSCs (LinSca1+cKit+CD150+CD48), and cycling HSCs (LinSca1+cKit+CD150+CD48+) among BM cells from DKO mice were greater than those from control mice (Fig. 1B and Fig. S2). In addition, lymphoid-primed multipotent progenitors (LMPPs; Lin Sca1+cKit+CD34+FLT3+), common lymphoid progenitors (CLPs; Lin Sca1lowcKitlow CD127+), common myeloid progenitors (CMPs; LinSca1cKit+CD34+CD16/32) and granulocyte-macrophage progenitors (GMPs; LinSca1cKit+CD34+CD16/32+) among BM cells from DKO mice were also increased in number, exhibiting increases comparable to or slightly less than those of HSCs (Fig. 1B). Mst1/2 deletion also led to a decrease in megakaryocyte-erythroid progenitors (MEPs; LinSca1cKit+CD34CD16/32) in the BM and a concomitant decrease in the number of erythroid cells in the BM (Fig. 1A,B). Finally, Mst1/2-deficient progenitors could grow ex vivo into colonies than that of control (Fig. 1C).

This HSC expansion phenotype also manifested in conventional Mst1-knockout mice. Notably, the absolute numbers of each HSC compartment in Mst1-deficient mice were also increased owing to a similar or slightly increased number of total BM cells compared with that in wild-type (WT) mice (Fig. S1A). However, conventional Mst2-knockout mice showed a modest increase in HSCs and progenitors (Fig. S1B). These results suggest that MST1/2 could function to limit the size of the HSC pool.

The expansion of HSC-enriched populations in Mst1/2-DKO mice is caused by increased proliferation and decreased apoptosis

To determine the cause of increased HSCs, we performed BrdU-incorporation assays in vivo. The proliferative activity of the HSC compartments, LSK and LSKFLT3-, were both increased in Mst1/2-DKO mice (Fig. 2A,B). It has been reported that MST1/2 kinases are crucial in mediating/promoting apoptosis under conditions that stimulate apoptosis17. Therefore, we analyzed whether altered apoptosis could contribute to the expansion of HSCs in Mst1/2-DKO mice. We found that there were fewer apoptotic (annexin V+/DAPI) cells in HSC compartments from the Mst1/2-DKO mouse (Fig. 2C,D). These data indicate that MST1/2 maintain HSC pools in vivo through regulation of proliferation and apoptosis.

Figure 2
figure 2

The frequency of proliferation is increased and the frequency of apoptosis is decreased in Mst1/2-DKO HSCs. (A) FACS plot showing BrdU-incorporating populations in [LSK]FLT3 cells. (B) Mst1/2-deficient HSCs showed greater proliferation than controls. (C) FACS plot showing annexin V+/DAPI populations in [LSK]FLT3 cells. (D) Mst1/2-deficient HSCs showed less apoptosis than control cells. Error bars indicate S.E.M. (*p ≤ 0.05, **p ≤ 0.01, n = 2).

HSCs were not exhausted in 6-month-old Mst1/2-DKO mice

Increased proliferation of HSCs leads to stem cell exhaustion, as exemplified by conditional Pten-deficient mice, which show stem cell depletion within 6 weeks after induction of Pten knockout (pIpC injection)25. To determine whether stem cells are depleted in Mst1/2-deficient mice, we analyzed the frequency of cells in HSC compartments 6 months after induction of Mst1/2 deletion by injection of pIpC (Fig. 3A and B). The frequencies of LSKs, HSCs and cycling HSCs were increased to levels similar to those in 3-week-old DKO mice, indicating that Mst1/2 DKO does not cause stem cell exhaustion. These data suggest that expansion of HSC numbers continued after Mst1/2 deletion and that the pools of these cells were maintained. Further, B cells were dramatically decreased in the BM, spleen and peripheral blood (PB) from in 6-month-old DKO mice as described before26 (Fig. 3C). We also found that DKO mice showed erythropenia in the BM and myeloid expansion in BM, spleen, and PB from in 6-month-old DKO mice. Collectively, we speculate that the reason why MST1/2 may expand HSC without exhaustion might be because MST1 and 2 modulate several functionally important targets in the other pathways that regulate an HSC program.

Figure 3
figure 3

HSCs were not exhausted in 6-month-old Mst1/2-DKO mice. (A) FACS plot showing the frequency of LSK, HSC and cycling HSC populations. (B) The frequency of LSK cells, HSCs, and cycling HSCs was increased in Mst1/2-DKO cells. Error bars indicate S.E.M. (*p ≤ 0.05, n = 2). (C) The frequencies of B cells (B220) and myeloid cells (monocytes, Mac1+Gr1lo; neutrophils, Mac1+Gr1+) in the BM, spleen and PB, and erythroid cells (TER119) in the BM, from mice of the indicated Mst1/2 genotypes are shown.

MST1/2 are required for HSC function under conditions of stress

To further test the function of Mst1/2-deficient HSCs, we transplanted BM cells from pIpC injected control or Mst1/2-DKO (CD45.2 cells) mice together with competitor cells into lethally irradiated CD45.1 mice. Competitors provided normal mature blood cells after reconstitution. Three weeks after transplantation, mice transplanted with Mst1/2-deficient cells displayed significantly diminished repopulation of mature blood cells compared with WT controls (Fig. 4A). This was caused by a decrease in HSCs and progenitor compartments of Mst1/2-deficient cells in transplanted recipient compared with control recipients (Fig. 4B). To examine donor chimerism of test cells following transplantation, we monitored repopulation maintenance in mice for 4 months. All cell lineages were detected throughout this period after transplantation, although the populations were lower than those in controls (Fig. 4C) and Mst1/2-deficient HSPCs were less well maintained at 4 months (Fig. 4D).

Figure 4
figure 4

MST1/2 play important roles in HSC engraftment. (A–D) pIpC was injected to induce Mx1-Cre at 3 weeks before CD45.2 test cell isolation. A 4:1 mixture of the indicated CD45.2 test cells was transplanted together with CD45.1 competitor cells. PB was collected and analyzed for CD45.2+ chimerism at 4 weeks (A and B) and 4 months (C and D) post-transplantation. (A and C) The frequencies of B cells, T cells, and myeloid cells in PB from transplant recipients are shown. (B and D) The frequencies of LSK cells and HSCs in BM from transplant recipients are shown. (E) The graph shows frequencies of myeloid cells in PB from secondary transplant recipients. (*p ≤ 0.05, **p ≤ 0.01, n = 3–5).

To determine whether Mst1/2-deficient HSCs are capable of surviving under secondary stress conditions, we performed a second transplantation of primary transplanted control and Mst1/2-deficient cells. We found that each hematopoietic cell lineage was less effectively reconstituted by Mst1/2-deficient HSCs. As was the case for primary transplantation, the reconstitution efficiency of secondarily transplanted Mst1/2-deficient cells was lower than that of control cells (Fig. 4E). These results indicate that MST1 and MST2 regulate BM engraftment efficiency.

The reduced homing activity of Mst1/2-deficient cells results in defective engraftment

Engraftment efficiency can be determined by homing ability and/or proliferation/differentiation. Based on the increased HSC proliferation in Mst1/2-deficient mice, we suspected a defect in homing ability or engraftment efficiency of Mst1/2-deficient cells. To test short-term engraftment, we transplanted control or Mst1/2-deficient BM cells into non-irradiated CD45.1 recipient mice and examined donor cell chimerism in BM, spleen and thymus 3 weeks post-transplantation. Mst1/2-deleted HSPCs showed a decreased frequency of donor cell chimerism compared with controls (Fig. 5A,B). We further assessed the homing ability of Mst1/2-deficient BM cells by transplanting CFSE-labeled control or Mst1/2-deficient BM cells into lethally irradiated CD45.1 recipient mice and examining CFSE+ cells in BM, spleen and PB 16 hours post-transplantation. Fewer resident Mst1/2-deficient cells were found in BM, spleen, and PB of recipient mice compared with transplanted control cells (Fig. 5C). Collectively, these data suggest that the regulation of HSC engraftment by MST1 and MST2 is due, at least in part, to effects on the homing step.

Figure 5
figure 5

Short-term engraftment function of MST1/2 in acute transplantation stress. (A and B) The frequencies of Mst1/2-deleted donor cell chimerism in BM, spleen, and thymus of recipient mice at 3 weeks post-transplantation are shown. (C) The frequencies of Mst1/2-deleted donor cell populations in BM, spleen, and PB of recipient mice at 16 hours post-transplantation are shown. (**p ≤ 0.01, n = 3–7).

Discussion

In this study, we demonstrated that an Mst1/2 deficiency leads to defects in the hematopoietic system. First, we found that Mst1/2 deletion markedly altered mature cell output. Conditional Mst1/2-deficient mice exhibited severe B cell lymphopenia, and an increase in the myeloid cell population and mild erythropenia in BM, spleen, and PB. Second, we found that the loss of Mst1/2 caused an increase in the steady state HSC population, a phenotype attributable to increased proliferation and reduced apoptosis of HSCs. However, stem cell exhaustion was not observed in 6-month-old Mst1/2-DKO mice, indicating that Mst1/2-deficient HSCs had expanded and were capable of maintaining their pools in the BM. Third, Mst1/2 knockout in HSCs did not induce hyperplasia or spontaneous hematopoietic neoplasms up to the time of death (D.H. Lee, D. Lee and D.S. Lim, unpublished data).

We further found that the function of Mst1/2-deficient HSCs was impaired under stress conditions. Mst1/2-deficient recipient mice exhibited fewer mature cells in PB and significantly decreased HSC chimerism in BM compared with controls. Interestingly, Mst1/2-deleted BM cells showed a decreased frequency of donor cell chimerism and differences in their short-term engraftment (3 weeks) and homing (16 hours) ability compared with controls under acute transplantation stress conditions. These data suggest that the inefficient engraftment of Mst1/2-deficient BM cells in the acute stress transplantation setting is attributable to decreased homing ability. Collectively, our findings suggest that Mst1 and Mst2 regulate HSC function in a setting of acute stress.

Numerous studies have reported that MST1 and MST2 are important in T cell migration18,27,28. By extension, it is reasonable to suggest that MST1 and MST2 are also essential for HSC migration into BM and adhesion to the BM microenvironment. Consistent with this, Mst1/2-deficient HSCs accumulated abnormally in PB and spleen, a phenomenon caused by defective HSC retention in the BM niche. Accordingly, we suggest that MST1 and MST2 will prove to be key factors for improving future human HSC transplantation therapies using cord blood or adult blood. In summary, MST1 and MST2 control the production of mature hematopoietic cells and play an indispensable role in the maintenance and function of hematopoietic stem and progenitor cells.